Drug intelligence / Profile preview

iodine-123 α-methyl-l-tyrosine

Development stage
Unknown
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Small Molecules
Administration
Intravenous
01

Overview

**Iodine-123 α-methyl-l-tyrosine** is a synthetic radiolabeled amino acid analog used as a radiopharmaceutical diagnostic agent, primarily for brain tumor imaging. It is transported predominantly by the System L amino acid transporter and accumulates in tumor tissues due to increased amino acid transport, but it is not incorporated into proteins. It is used in single-photon emission computed tomography (SPECT) to detect and differentiate recurrent gliomas from benign post-therapeutic lesions. Its uptake correlates with the proliferative activity of tumor cells, and it may aid in therapy planning for glioma patients. The mechanism is based on high tumor-specific uptake by the L-type amino acid transport system, associated with 4F2 antigen expression, but does not target a signaling or metabolic pathway directly[1][2][4].

Other names
3-[(123)I]iodo-α-methyl-L-tyrosine3-[123I]iodo-α-methyl-L-tyrosine3-iodo-α-methyl-L-tyrosine123I-IMTIMT-SPET
02

Targets

SLC7A5 (Large neutral amino acid transporter small subunit 1)LAT2 (Linker for activation of T cells family member 2)

Beyond the preview

Go deeper on iodine-123 α-methyl-l-tyrosine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on iodine-123 α-methyl-l-tyrosine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call